MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast - Episode Library
  • Patient Community Day at ECTRIMS 2025
  • Multiple Sclerosis in 2025 – Key Developments to Date
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
two doctors, a man and a woman, examine an MRI image of the brain

FDA Decision On Tolebrutinib

MStranslate
January 12, 2026
Clinical Trials
A pair of hands around a crystal ball that has the year 2026 written inside it.

Multiple Sclerosis Research In 2026

MStranslate
January 5, 2026
Progressive MS, Remyelination, Treatments
ECTRIMS Congress 2025

Revisiting ECTRIMS Congress 2025

MStranslate
November 18, 2025
ECTRIMS, Podcasts, Research
The ECTRIMS Podcast

UPDATED: The ECTRIMS Podcast – Episode Library

MStranslate
September 10, 2025
ECTRIMS, Podcasts, Research
Patient Community Day

Patient Community Day at ECTRIMS 2025

MStranslate
July 22, 2025
ECTRIMS, Events, Research

Eye Movement Research in Multiple Sclerosis

MStranslate
June 30, 2014
Ocular Motor
Associate Professor and Neuro-ophthalmologist, Owen White MD, introduces the Melbourne Brain Centre's Ocular Motor research team and talks about eye movement research in relation to multiple...

MERTK – A Susceptibility Gene in Multiple Sclerosis

MStranslate
May 28, 2014
Basic Sciences, Research
Professor Trevor Kilpatrick, Director of the Melbourne Neuroscience Institute, discusses the discovery of a new susceptibility gene for multiple sclerosis, MERTK.  The video highlights how this gene was...

Genetics & Multiple Sclerosis – A/Prof Helmut Butzkueven

MStranslate
May 28, 2014
Basic Sciences, Research
Associate Professor Helmut Butzkueven discusses the importance of understanding the genetic markers of multiple sclerosis and explains the research currently being undertaken by the Basic Sciences team in...

A New Marker to Predict MS Progression

MStranslate
May 27, 2014
Basic Sciences
When people are diagnosed with MS, it is very difficult to predict how their condition will progress as each individual will often have different outcomes. This leads to a large level of uncertainty for the...

The PET/CT Scanner & Its Uses for Multiple Sclerosis

MStranslate
May 2, 2014
Neuroimaging
Professor Roger Ordidge, Chair of Imaging Science at the University of Melbourne, provides an insight into the new PET/CT scanner located at the Melbourne Brain Centre and explains how it might help people...

An Explanation of Magnetic Resonance Imaging (MRI)

MStranslate
May 1, 2014
Neuroimaging
As magnetic resonance imaging (MRI) plays a key role in the diagnosis of multiple sclerosis, we took the opportunity to ask Professor Roger Ordidge, Chair of Imaging Science at The University of Melbourne,...

A New Technique to Assess Outcomes of Optic Neuritis

MStranslate
April 30, 2014
Neuroimaging
Optic neuritis (inflammation of the optic nerve, (ON)) causes visual loss and is a common early symptom of multiple sclerosis (MS). Patients with ON present to hospital early and identifying measurements of...

Understanding the Different Outcomes of Optic Neuritis

MStranslate
April 29, 2014
Neuroimaging, Research
Optic neuritis (inflammation of the optic nerve) is a common side-effect of multiple sclerosis (MS) and leads to many sight-related difficulties, including blurriness, impaired colour recognition and problems...

An Introduction to the PrevANZ Trial

MStranslate
March 28, 2014
Lifestyle, Research, Vitamin D
Filmed during our MSBase Feature Week, this short video with Associate Professor Helmut Butzkueven introduces PrevANZ, a Multiple Sclerosis Research Australia led study investigating the role Vitamin D...

Fingolimod After Natalizumab & Short-term Relapse Risk

MStranslate
March 27, 2014
Fingolimod, Natalizumab, Research, Treatments
Dr Vilija Jokubaitis et al Natalizumab (Tysabri) is an antibody used for the treatment of multiple sclerosis (MS). It is currently the strongest drug available for the treatment of MS, however, it has also...
  1. 27
  2. 28
  3. 29
  4. 30
  5. 31
  6. 32
  7. 33

Recent Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Recent Comments

  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date
  • Treatment With Gut Bacteria Shows Benefits In New Study on Gut Bacteria in People Living with RRMS
  • Community Q&A: COVID-19 Vaccines & Multiple Sclerosis on Community Q&A: The Blood-Brain Barrier
  • Community Q&A: Why Don't We Have A Multiple Sclerosis Cure? on Community Q&A: COVID-19 Vaccines & MS
  • Tim Little on FAKE NEWS ALERT: COVID Vaccines & MS

Calendar

March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Jan    

Archives

Categories

Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.